on AELIS FARMA (isin : FR0014007ZB4)
Availability of the 2025 half-year financial report by Aelis Farma
Aelis Farma, a biopharmaceutical company specializing in treatments for brain and peripheral diseases, announces the publication of its 2025 half-year financial report. The document is available on the company's website. It has also been filed with the French Financial Markets Authority (Autorité des Marchés Financiers). This milestone underscores Aelis Farma's commitment to financial transparency.
This Bordeaux-based company, founded in 2013, is developing a new class of drugs, CB1 receptor specific signaling inhibitors (CB1-SSi). It has clinical-stage drug candidates for cannabis addiction and cognitive disorders.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AELIS FARMA news